|
AAP Committee on fetus and newborn
|
| bet | 84/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
| AAP Committee on fetus and newborn: Caffeine citrate is a safe and effective treatment of apnea of prematurity when administered at a 20-mg/kg loading dose and 5 to 10 mg/kg per day maintenance. Monitoring routine serum caffeine levels usually is not contributory to management. A trial off caffeine may be considered when an infant has been free of
clinically significant apnea/bradycardia events off positive pressure for 5 to 7 days or at 33 to 34 weeks’ PMA, whichever comes first. [2] However, caffeine may not reach subtherapeutic levels until 11-12 days post-cessation [6].
|
| |
